Search Results
You are looking at 1 - 2 of 2 items for
- Author: Mei Yu x
- Refine by access: All content x
Search for other papers by Lili Guo in
Google Scholar
PubMed
Search for other papers by Penghua Fang in
Google Scholar
PubMed
Search for other papers by Mei Yu in
Google Scholar
PubMed
Search for other papers by Mingyi Shi in
Google Scholar
PubMed
Department of Endocrinology, Medical College, Department of Physiology, Department of Physical Education, Clinical Medical College, Yangzhou University, Nantong West Street No. 98, Yangzhou, Jiangsu 225001, China
Search for other papers by Ping Bo in
Google Scholar
PubMed
Search for other papers by Zhenwen Zhang in
Google Scholar
PubMed
Alarin, a regulatory peptide, belongs to the galanin family and plays the same regulatory roles as galanin in orexigenic activity and energy metabolism. Our previous studies had found that galanin might facilitate insulin sensitivity via activation of its central receptors. To date, little is known about whether central alarin may exert similar effects on insulin sensitivity. In order to investigate this, alarin and its specific antagonist, alarin 6–25Cys, were administered into the cerebral ventricles of type 2 diabetic rats (T2DR) to evaluate the changes in insulin resistance. The results indicated that central treatment with alarin significantly increased the body weight of animals, the 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose uptake, the plasma adiponectin levels, the glucose infusion rates in hyperinsulinemic–euglycemic clamp tests, the vesicle-associated membrane protein 2 as well as glucose transporter 4 (GLUT4 (SLC2A4)) protein and mRNA levels, and the ratios of GLUT4 contents in plasma membranes to total cell membranes in adipocytes, but reduced blood glucose and plasma retinol-binding protein 4 levels. These effects of alarin may be inhibited by pretreatment with alarin 6–25Cys. The above-mentioned results suggest that the central alarin projective system may facilitate insulin sensitivity and glucose uptake via the increase in GLUT4 content and GLUT4 translocation from intracellular pools to plasma membranes in T2DR.
Search for other papers by Xuanchun Wang in
Google Scholar
PubMed
Search for other papers by Wei Gong in
Google Scholar
PubMed
Search for other papers by Yu Liu in
Google Scholar
PubMed
Search for other papers by Zhihong Yang in
Google Scholar
PubMed
Search for other papers by Wenbai Zhou in
Google Scholar
PubMed
Search for other papers by Mei Wang in
Google Scholar
PubMed
Search for other papers by Zhen Yang in
Google Scholar
PubMed
Search for other papers by Jie Wen in
Google Scholar
PubMed
Search for other papers by Renming Hu in
Google Scholar
PubMed
We report the identification of a novel secreted peptide, INM02. The mRNA transcript of human INM02 gene is about 3.0 kb. Its open-reading frame contains 762 bps and encodes a protein of 254 amino acids. Northern blot analysis demonstrates that INM02 mRNA is widely expressed in rat tissues, especially with abundant quantities in pancreatic islets, testis, and bladder tissue. We have expressed recombinant INM02 protein and generated rabbit anti-INM02 polyclonal antibodies. We show here that INM02 could be detectable in human serum by ELISA. We also present evidence that INM02 mRNA expression could be regulated by glucose. Experiments on both MIN6 cells and intact isolated islets demonstrate that INM02 mRNA levels are increased more than threefold by high glucose (25 mM) when compared with low glucose (5.5 mM). ELISA analysis shows that secretion of INM02 is significantly augmented by high glucose in vitro. It is speculated that as a novel secreted protein, INM02 is associated with functions of pancreatic islets, especially of β-cells.
